The group's principal activity is to design, develop and commercialize therapeutic products based on proprietary delivery systems. The group develops products for topical treatments including cream, gel, patch and tape products based on a penetration enhancement technology known as nexact (r). Nexact enables an active drug to be better absorbed through the skin. The products under development include alprox-td(R), femprox (TM) and viratrol (r). Alprox-td(R) and femprox(R) creams are used for the treatment of male erectile dysfunction and female sexual arousal disorder respectively. Viratrol(R) is a therapeutic medical device for the treatment of herpes simplex diseases without the use of drugs. The group has international operations in Hong Kong and Canada.
